Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer

RETAIN-3 is a phase II study in patients with cT2-T3N0M0 muscle-invasive urothelial carcinoma of the bladder. Participants will receive neoadjuvant enfortumab vedotin and pembrolizumab followed by clinical and biomarker-based assessment to inform subsequent treatment management.

Trial Details

NCT ID

NCT07908979

Phase

PHASE2

Sponsor

Fox Chase Cancer Center

Status

RECRUITING

Cancer Type

Bladder Cancer

Interventions

Enfortumab vedotin
Pembrolizumab
Cisplatin
Gemcitabine
Fluorouracil
Mitomycin c

Locations (sample)

Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

Primary urothelial or predominantly urothelial carcinoma of the bladder confirmed from pathology report. Patients with some component of variant hi…
Urothelial carcinoma of the prostatic urethra in men is allowed
Histologic evidence of muscularis propria invasion.
AJCC(22) clinical stage T2-T3 N0M0.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →